JP2008520719A - チューブリン結合抗癌剤およびそれらのプロドラッグ - Google Patents

チューブリン結合抗癌剤およびそれらのプロドラッグ Download PDF

Info

Publication number
JP2008520719A
JP2008520719A JP2007543334A JP2007543334A JP2008520719A JP 2008520719 A JP2008520719 A JP 2008520719A JP 2007543334 A JP2007543334 A JP 2007543334A JP 2007543334 A JP2007543334 A JP 2007543334A JP 2008520719 A JP2008520719 A JP 2008520719A
Authority
JP
Japan
Prior art keywords
alkylamino
hydrogen
aryl
amino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007543334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520719A5 (enExample
Inventor
マーク マッテウッチ
ジャン−シン ドゥアン
シャオホン カイ
Original Assignee
スレショルド ファーマシューティカルズ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレショルド ファーマシューティカルズ インコーポレイティッド filed Critical スレショルド ファーマシューティカルズ インコーポレイティッド
Publication of JP2008520719A publication Critical patent/JP2008520719A/ja
Publication of JP2008520719A5 publication Critical patent/JP2008520719A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007543334A 2004-11-22 2005-11-17 チューブリン結合抗癌剤およびそれらのプロドラッグ Withdrawn JP2008520719A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63042204P 2004-11-22 2004-11-22
US72692805P 2005-10-14 2005-10-14
PCT/US2005/042095 WO2006057946A2 (en) 2004-11-22 2005-11-17 Tubulin binding anti cancer agents and prodrugs thereof

Publications (2)

Publication Number Publication Date
JP2008520719A true JP2008520719A (ja) 2008-06-19
JP2008520719A5 JP2008520719A5 (enExample) 2009-01-22

Family

ID=36498450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543334A Withdrawn JP2008520719A (ja) 2004-11-22 2005-11-17 チューブリン結合抗癌剤およびそれらのプロドラッグ

Country Status (10)

Country Link
US (1) US20090042820A1 (enExample)
EP (1) EP1819338A4 (enExample)
JP (1) JP2008520719A (enExample)
KR (1) KR20070086595A (enExample)
AU (1) AU2005309761A1 (enExample)
CA (1) CA2587210A1 (enExample)
IL (1) IL183212A0 (enExample)
MX (1) MX2007006102A (enExample)
NO (1) NO20073211L (enExample)
WO (1) WO2006057946A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530211A (ja) * 2010-07-06 2013-07-25 サノフイ イミダゾピリジン誘導体、それらを調製するための方法およびそれらの治療上の使用
JP2016537308A (ja) * 2013-09-27 2016-12-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための化合物及び方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
KR20090025367A (ko) * 2006-06-28 2009-03-10 가부시키가이샤산와카가쿠켄큐쇼 신규 6-5계 이환식 복소환 유도체 및 그 의약용도
ES2884044T3 (es) 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
WO2008124691A1 (en) 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2008151253A1 (en) * 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
JP5765634B2 (ja) 2008-10-21 2015-08-19 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド 低酸素活性化型プロドラッグを用いるがんの処置
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為ｌｓｄ１抑制劑之環丙胺
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
US10829437B2 (en) * 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
US20180169064A1 (en) 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11427591B2 (en) * 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
CN115403483B (zh) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
ATE368046T1 (de) * 2000-03-10 2007-08-15 Univ Baylor Tubulin bindende liganden
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1506960B1 (en) * 2003-08-07 2011-04-06 National Health Research Institutes Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530211A (ja) * 2010-07-06 2013-07-25 サノフイ イミダゾピリジン誘導体、それらを調製するための方法およびそれらの治療上の使用
JP2016537308A (ja) * 2013-09-27 2016-12-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための化合物及び方法

Also Published As

Publication number Publication date
EP1819338A4 (en) 2009-11-04
NO20073211L (no) 2007-08-21
IL183212A0 (en) 2008-04-13
WO2006057946A2 (en) 2006-06-01
CA2587210A1 (en) 2006-06-01
MX2007006102A (es) 2007-07-11
AU2005309761A1 (en) 2006-06-01
KR20070086595A (ko) 2007-08-27
WO2006057946A3 (en) 2007-07-05
EP1819338A2 (en) 2007-08-22
US20090042820A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
JP2008520719A (ja) チューブリン結合抗癌剤およびそれらのプロドラッグ
KR101198526B1 (ko) 암 치료를 위한 조성물 및 방법
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
JP5406716B2 (ja) インドール化合物
RU2414475C2 (ru) Пролекарства фосфорамидатных алкилаторов
ES2289349T3 (es) Derivados de heteroaril-pirimidina como inhibidores de jak.
US8575188B2 (en) Camptothecin derivatives
US20070043057A1 (en) Lonidamine analogs
WO2005086951A2 (en) Hypoxia-activated anti-cancer agents
US20080214576A1 (en) Topoisomerase Inhibitors and Prodrugs
CN101094838A (zh) 微管蛋白结合抗癌药及其前体药物
WO2007137196A2 (en) Tubulin binding anti cancer compounds and prodrugs thereof
HK1136563A (en) Indole compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081114

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091016